Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91 & TA 222)

Comments on the ACD

This report was commissioned by the NIHR HTA Programme as project number 10/108

BMJ Technology Assessment Group

This document contains comments on the ACD for *topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91 & TA 222).*

Page No.	**Change**
Page 23, Paragraph 4.2.13	Suggested text change for administration costs. The figures stated in 4.2.13 are the sum of first administration cost and subsequent administration cost. In fact, there are likely to be further administrations at the "subsequent" cost, depending upon how many subsequent cycles the patient completes. Alternative text suggestion: *The model assumed that treatment regimens would be administered as an infusion in a hospital and associated administration costs were included in the model. The estimated administration costs in the model were assumed to differ for the first administration, and all subsequent administrations. The estimated first cycle administration cost in the model were £363 for 3-weekly paclitaxel plus carboplatin, £215 for weekly paclitaxel, £265 for PLDH, £363 for PLDH plus carboplatin, £567 for gemcitabine plus carboplatin, £363 for trabectedin plus PLDH and £1,359 for topotecan. The estimated administration cost for all subsequent cycles in the model were £302 for 3-weekly paclitaxel plus carboplatin, £286 for weekly paclitaxel, £286 for PLDH, £302 for PLDH plus carboplatin, £588 for gemcitabine plus carboplatin, £302 for trabectedin plus PLDH and £1,430 for topotecan. For the base-case analyses, it was assumed that no vial sharing would occur.*
Page 27, Paragraph 4.2.19	The ICER for trabectedin plus PLDH versus PLDH estimated by the TAG should be £35,646 and not £35,363.
Page 27, Paragraph 4.2.20	Third sentence should begin "topotecan versus PLDH", not "topotecan plus PLDH";
Page 27, Paragraph 4.2.20	Fourth sentence should be "The resulting ICERs for topotecan compared with PLDH alone..." rather than "topotecan plus PLDH compared with..."